Article info
PDFBrief report
Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
- Correspondence to Dr Catherine Rhodes, Institute for Science, Ethics and Innovation, School of Law, Williamson Building, University of Manchester, Oxford Road, Manchester, UK; catherine.rhodes-2{at}manchester.ac.uk
Citation
Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
Publication history
- Received June 6, 2011
- Revised August 2, 2011
- Accepted August 7, 2011
- First published September 24, 2011.
Online issue publication
June 29, 2021
Article Versions
- Previous version (29 June 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Why using Avastin for eye disease is so difficult
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- Implications of “not me” drugs for health systems: lessons from age related macular degeneration
- Why have UK doctors been deterred from prescribing Avastin?
- What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?
- Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review